Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 418 results found since Jan 2013.
Continued Exploration of the Mechanisms of Cellular Senescence
Today, a pair of papers that are representative of present interest in the deeper mechanisms of cellular senescence. Senescent cells have of late become a major focus in the aging research community, now that scientists are largely convinced that (a) accumulation of these cells is a significant cause of aging, and (b) removing them can reverse aging and age-related disease to a large enough degree to justify significant investment in further development. Better late than never! The evidence has been compelling for decades, but only in 2011 was sufficient funding raised by a sufficiently well-regard research group to build ...
Source: Fight Aging! - January 28, 2019 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
A stage IV lung cancer survivor story
I want to share how the era of immunotherapy, specifically immune-checkpoint-inhibitors, has changed the landscape of community oncology practice in metastatic non-small-cell lung cancer, for oncologists and, more importantly, patients. I want to tell you the story of Joe. A stage IV lung cancer survivor story. (Name and details changed to protect anonymity.) In 2015, Joe […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more.
Source: Kevin, M.D. - Medical Weblog - January 23, 2019 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/jennifer-lycette" rel="tag" > Jennifer Lycette, MD < /a > < /span > Tags: Conditions Oncology/Hematology Pulmonology Source Type: blogs
Immunotherapy: What you need to know
Not all that long ago, chemotherapy was the only option to treat most advanced (metastatic) cancers. Because these drugs work by destroying rapidly dividing cells, they harm some healthy cells — such as hair follicles — as well as cancer cells. In the past two decades, cancer treatment has been transformed by targeted drugs and the emergence of chemotherapy. Targeted drugs are designed to home in on specific genes or proteins that are altered or overexpressed on cancer cells. Immunotherapy has been very successful for certain types of advanced cancers, such as lung, bladder, and skin cancers.
One form of immunotherapy ...
Source: Harvard Health Blog - January 22, 2019 Category: Consumer Health News Authors: Guru P. Sonpavde, MD Tags: Cancer Immunotherapy Managing your health care Source Type: blogs
Fight Aging! Newsletter, January 21st 2019
In this study, scientists screened cells from old animals to identify any RBPs that change upon aging. The screening showed that one particular protein, Pumilio2 (PUM2), was highly induced in old animals. PUM2 binds mRNA molecules containing specific recognition sites. Upon its binding, PUM2 represses the translation of the target mRNAs into proteins.
Using a systems genetics approach, the researchers then identified a new mRNA target that PUM2 binds. The mRNA encodes for a protein called Mitochondrial Fission Factor (MFF), and is a pivotal regulator of mitochondrial fission - a process by which mitochondria break u...
Source: Fight Aging! - January 20, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Fight Aging! Newsletter, January 14th 2019
In conclusion, reduction of LDL-C to less than 50 mg/dl seems safe and provides greater CV benefits compared with higher levels. Data for achieved LDL-C lower than 20-25 mg/dl is limited, although findings from the above mentioned studies are encouraging. However, further evaluation is needed for future studies and post-hoc analyses.
Wary of the Beautiful Fairy Tale of Near Term Rejuvenation
https://www.fightaging.org/archives/2019/01/wary-of-the-beautiful-fairy-tale-of-near-term-rejuvenation/
One might compare this interview with researcher Leonid Peshkin to last year's discussion with Vadim Gladyshev. ...
Source: Fight Aging! - January 13, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Fight Aging! Newsletter, January 7th 2019
This study suggests that advantages and disadvantages vary by environment and diet, however, which might explain why evolution has selected for multiple haplogroups rather than one dominant haplogroup.
This is all interesting, but none of it stops the research community from engineering a globally better-than-natural human mitochondrial genome, and then copying it into the cell nucleus as a backup to prevent the well-known contribution of mitochondrial DNA damage to aging. Further, nothing stops us from keeping the haplogroups we have and rendering the effects of variants small and irrelevant through the development...
Source: Fight Aging! - January 6, 2019 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Last Month in Oncology with Dr. Bishal Gyawali
By BISHAL GYAWALI MD
Long list of news in lung cancer
September was an important month in oncology—especially for lung cancer. The World Conference in Lung Cancer (WCLC) 2018 gave us some important practice-changing results, also leading to four NEJM publications. The trial with most public health impact is unfortunately not published yet. It’s the NELSON trial that randomised more than 15000 asymptomatic people at high risk of lung cancer to either CT-based screening for lung cancer or to no screening and found a significant reduction in lung cancer mortality rates among the screened cohort compared with the contr...
Source: The Health Care Blog - January 4, 2019 Category: Consumer Health News Authors: matthew holt Tags: Research Bishal Gyawali Breast cancer Cancer drugs Clinical Trials health spending immunotherapy Lung cancer Oncology pembrolizumab Source Type: blogs
A Look Back at the Rejuvenation Research and Advocacy of 2018
Discussion of Mitochondrial Hormesis as an Approach to Slow Aging
Cornelis (Cees) Wortel, Ichor Therapeutics Chief Medical Officer, on Rejuvenation Research and Its Engagement with the Established Regulatory System
An Interview with a Programmed Aging Theorist
An Interview with Reason at the Life Extension Advocacy Foundation
An Interview on Mitochondrial Damage and Dysfunction in Aging
An Interview with Vadim Gladyshev on Research into the Causes of Aging
An Interview with Jim Mellon, and Update on Juvenescence
A Lengthy Interview with Aubrey de Grey of the SENS Research Foundation
An Interview with Peter de Keize...
Source: Fight Aging! - December 31, 2018 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs
Last Month in Oncology with Dr. Bishal Gyawali: November 2018
By BISHAL GYAWALI MD
Keynote speech
There was a very sobering piece in NEJM by the FDA last month in which the authors try to explore what went wrong with the Keynote-183, Keynote-185 and checkmate 602 trials testing PD-1 inhibitors combinations with pomalidomide or lenalidomide and dexamethasone in multiple myeloma. Interim analysis of Keynote 183 and 185 revealed detrimental effects on overall survival (OS) with hazard ratios of 1.61 and 2.06, not explained by differences in toxicities alone. The checkmate 602 trial was also halted in light of these findings and also showed higher mortality in the nivolumab combina...
Source: The Health Care Blog - December 17, 2018 Category: Consumer Health News Authors: matthew holt Tags: Pharmaceuticals Physicians Bishal Gyawali Cancer drugs cancer immunotherapy Clinical Trials FDA Oncology PD-1 inhibitors Source Type: blogs
Fight Aging! Newsletter, December 10th 2018
In conclusion, this is the first report to show that pyroptotic cell death occurs in the aging brain and that the inflammasome can be a viable target to decrease the oxidative stress that occurs as a result of aging.
Reducing Levels of Protein Manufacture Slows Measures of Aging in Nematodes
https://www.fightaging.org/archives/2018/12/reducing-levels-of-protein-manufacture-slows-measures-of-aging-in-nematodes/
Researchers here demonstrate that an antibiotic slows aging in nematode worms, providing evidence for it to work through a reduction in protein synthesis. Beyond a slowing of aging, one of the con...
Source: Fight Aging! - December 9, 2018 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
The Current State of Therapeutic Development Involving Induced Pluripotent Stem Cells
A little more than a decade has passed since the development of a simple cell reprogramming approach that reliably created pluripotent stem cells from ordinary somatic cells, known as induced pluripotent stem cells. These stem cells are very similar, near identical in fact, to the embryonic stem cells that were previously the only reliable source of cells capable of forming any cell type in the body. Arguably the most important aspect of induced pluripotency is not the promise of the ability to generate patient-matched cells for regenerative therapies and tissue engineering of replacement organs, but rather that it is a lo...
Source: Fight Aging! - December 4, 2018 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Fight Aging! Newsletter, November 19th 2018
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more.
This content is...
Source: Fight Aging! - November 18, 2018 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Initial Evidence for the Antibiotics Azithromycin and Roxithromycin to be Senolytic
Researchers here report on two new senolytic compounds identified in the existing library of approved drugs, based on screening work in cell cultures. It is worth bearing in mind that drug candidates that demonstrate good results in cell culture quite often fail to show promise when tested in animals, so it is wise to be patient as new senolytics work their way through the research and development pipeline. There will be a lot more of this sort of thing in the years ahead, as ever greater amounts of funding pour into finding new ways to selectively destroy senescent cells. Any senolytic approach that removes a significant ...
Source: Fight Aging! - November 16, 2018 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Senolytic Therapeutics Uses Nanotube-Carried Toxins to Destroy Senescent Cells
Today, I'll point out an analysis from the SENS Research Foundation that covers the approach to selective destruction of senescent cells taken by one of the newly formed biotech startups in the space, Senolytic Therapeutics. This field is hot because it is now well proven that senescent cells are the enemy. They are one of the root causes of aging, accumulating with age to degrade tissue function via the secretion of inflammatory signal molecules. Senescent cells actively maintain an aged, inflamed state of metabolism, resulting in the development of age-related disease and increased mortality.
Senescent cells do se...
Source: Fight Aging! - November 14, 2018 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
A Popular Science View of Checkpoint Inhibitor Cancer Immunotherapies
Checkpoint inhibitor therapies are a demonstrably successful approach to cancer immunotherapy. They suppress a mechanism that normally restrains immune cells from attacking other cells. This mechanism is abused by cancers, alongside a variety of other ways in which the immune system can be subverted or quieted. Any advanced tumor tends to have evolved into a state in which it is ignored or even helped by the immune system. Checkpoint inhibitor therapies are an improvement on chemotherapy when it comes to the trade-off between harming the cancer and harming the patient, as well as in the odds of success, but still present r...
Source: Fight Aging! - November 13, 2018 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
